MCID: ORL007
MIFTS: 59

Oral Cavity Cancer malady

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases

Aliases & Classifications for Oral Cavity Cancer

Aliases & Descriptions for Oral Cavity Cancer:

Name: Oral Cavity Cancer 12 29 14
Malignant Neoplasm of Anterior Portion of Floor of Mouth 12
Malignant Neoplasm of Lateral Portion of Floor of Mouth 12
Malignant Neoplasm of Lateral Floor of Mouth 12
Malignant Tumor of Anterior Floor of Mouth 12
Malignant Tumor of Lateral Floor of Mouth 12
Malignant Tumor of the Floor of the Mouth 12
Malignant Neoplasm of Floor of Mouth 12
Malignant Neoplasm of Mouth 69
Oral Cavity Carcinoma 69

Classifications:



Summaries for Oral Cavity Cancer

Disease Ontology : 12 A gastrointestinal system cancer that is located in the oral cavity.

MalaCards based summary : Oral Cavity Cancer, also known as malignant neoplasm of anterior portion of floor of mouth, is related to lip and oral cavity cancer and oral squamous cell carcinoma. An important gene associated with Oral Cavity Cancer is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Development Endothelin-1/EDNRA signaling. The drugs Ethanol and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include lymph node, neutrophil and lung, and related phenotypes are Decreased viability with paclitaxel and cardiovascular system

Related Diseases for Oral Cavity Cancer

Diseases in the Oral Cavity Cancer family:

Oral Cavity Carcinoma in Situ

Diseases related to Oral Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
id Related Disease Score Top Affiliating Genes
1 lip and oral cavity cancer 12.2
2 oral squamous cell carcinoma 10.9
3 salivary gland cancer 10.9
4 pineal region mature teratoma 10.4 EGFR ERBB2
5 ovarian cystadenocarcinoma 10.3 EGFR ERBB2 VEGFA
6 adult central nervous system immature teratoma 10.3 ERBB2 MCL1
7 spongiotic dermatitis 10.3 CYP1A1 EGFR ERBB2
8 anaerobic meningitis 10.3 EGFR TNFRSF10B VEGFA
9 immunodeficiency due to a late component of complement deficiency 10.3 EGFR ERBB2 VEGFA
10 lichen planus pigmentosus 10.3 CYP1A1 GSTM1 GSTT1
11 multinodular goiter 10.3 EGFR ERBB2 VEGFA
12 esophageal neuroendocrine tumor 10.3 CYP1A1 GSTM1 GSTT1
13 marginal zone b-cell lymphoma 10.3 CASP8 EGFR TNFRSF10B VEGFA
14 dental caries 10.3 EGFR ERBB2 VEGFA
15 ornithinemia 10.3 CYP1A1 EGFR GSTM1 GSTT1
16 nasal cavity disease 10.3 EGFR ERBB2 VEGFA
17 emery-dreifuss muscular dystrophy, x-linked 10.3 CYP2E1 GSTM1 GSTT1
18 malignant pleural solitary fibrous tumor 10.3 EGFR ERBB2 SOX2 VEGFA
19 lower lip cancer 10.2 CASP8 EGFR ERBB2
20 cervical adenomyoma 10.2 ALDH2 CYP2E1 GSTM1
21 placenta praevia 10.2 EGFR ERBB2 GSTM1 GSTT1 VEGFA
22 ladd syndrome 10.2 EGFR ERBB2 GSTM1 GSTT1 VEGFA
23 rapsn-related fetal akinesia deformation sequence 10.2 CYP1A1 CYP2E1 GSTM1 GSTT1
24 pituitary stalk meningioma 10.2 ERBB2 GSTM1 GSTT1
25 prostatic adenoma 10.2 EGFR ERBB2 VEGFA
26 ocular melanoma 10.2 CYP1A1 EGFR ERBB2 VEGFA
27 anal fistula 10.2 ALDH2 CYP2E1 GSTM1
28 hypogonadotropic hypogonadism 20 with or without anosmia 10.2 EGFR ERBB2 GSTM1 GSTT1 TNFRSF10B VEGFA
29 necrobiosis lipoidica 10.2 CAT CYP1A1 ERBB2
30 plague 10.2 CASP8 EGFR ERBB2
31 nail disorder, nonsyndromic congenital, 3, 10.1 ALDH2 CYP1A1 EGFR ERBB2 GSTM1 VEGFA
32 pancreatic cystadenoma 10.1 CYP1A1 EGFR SOX2
33 cardiomyopathy, dilated, 1h 10.0 CASP8 CYP1A1 CYP2E1 LIN28B MCL1 TNFRSF10B
34 split-hand/foot malformation with long bone deficiency 1 9.9 CASP8 EGFR ERBB2 GDF15 GSTM1 HSP90B1
35 thrombocytopenic purpura, autoimmune 9.9 CASP8 CYP1A1 CYP2E1 EGFR ERBB2 GSTM1
36 colorectal cancer 9.8 CASP8 CYP1A1 EGFR ERBB2 GDF15 GSTM1
37 leukoplakia 9.7
38 hepatitis 9.6
39 mucositis 9.6
40 hepatitis c 9.6
41 pharyngitis 9.6
42 papilloma 9.6
43 encephalopathy 9.6
44 uvula cancer 9.0 ALDH2 CASP8 CAT CYP1A1 CYP2E1 EDNRB

Comorbidity relations with Oral Cavity Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oral Cavity Cancer:



Diseases related to Oral Cavity Cancer

Symptoms & Phenotypes for Oral Cavity Cancer

GenomeRNAi Phenotypes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 EGFR ERBB2 FADD
2 Decreased viability with paclitaxel GR00179-A-3 8.92 EGFR

MGI Mouse Phenotypes related to Oral Cavity Cancer:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.33 CASP8 CYP1A1 CYP2E1 EDNRB EGFR ERBB2
2 cellular MP:0005384 10.31 MCL1 SOX2 VEGFA ALDH2 CASP8 CAT
3 growth/size/body region MP:0005378 10.29 SOX2 VEGFA ALDH2 CASP8 CYP1A1 EDNRB
4 homeostasis/metabolism MP:0005376 10.28 GDF15 IL18 LIN28B SOX2 VEGFA ALDH2
5 embryo MP:0005380 10.21 CASP8 EDNRB EGFR ERBB2 FADD HSP90B1
6 hematopoietic system MP:0005397 10.2 ALDH2 CASP8 CYP1A1 EGFR FADD GDF15
7 endocrine/exocrine gland MP:0005379 10.19 ALDH2 CASP8 CYP1A1 EDNRB EGFR ERBB2
8 immune system MP:0005387 10.18 ALDH2 CASP8 CYP1A1 EDNRB EGFR FADD
9 mortality/aging MP:0010768 10.16 FADD GDF15 HSP90B1 IL18 LIN28B MCL1
10 digestive/alimentary MP:0005381 10.07 EDNRB EGFR ERBB2 FADD IL18 SOX2
11 integument MP:0010771 10.02 ALDH2 CASP8 EDNRB EGFR ERBB2 IL18
12 liver/biliary system MP:0005370 9.92 VEGFA ALDH2 CASP8 CYP1A1 CYP2E1 EGFR
13 muscle MP:0005369 9.81 CASP8 EDNRB EGFR ERBB2 FADD IL18
14 neoplasm MP:0002006 9.61 ALDH2 CASP8 CAT CYP2E1 EDNRB EGFR
15 nervous system MP:0003631 9.36 FADD GDF15 IL18 LIN28B SOX2 VEGFA

Drugs & Therapeutics for Oral Cavity Cancer

Drugs for Oral Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1133)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
4
Nicotine Approved Phase 4 54-11-5 942 89594
5
Pravastatin Approved Phase 4 81093-37-0 54687
6
Zinc Approved Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
7
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-28-2 5757 53477783
8
Vinblastine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 865-21-4 13342 241903
9
Digoxin Approved Phase 4,Phase 2,Phase 1 20830-75-5 30322 2724385
10
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
11
Irinotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
12
Vinorelbine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 71486-22-1 60780 44424639
13
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 1 51-43-4 5816
14
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
15
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 1 59467-70-8 4192
16
Erythromycin Approved, Vet_approved Phase 4,Phase 2,Phase 1 114-07-8 12560
17
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
18
Diclofenac Approved, Vet_approved Phase 4,Phase 2 15307-86-5 3033
19
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 57-27-2 5288826
20
Acetaminophen Approved Phase 4,Phase 2,Phase 3,Phase 1 103-90-2 1983
21
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
22
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
23
Ribavirin Approved Phase 4,Phase 1,Phase 2 36791-04-5 37542
24
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 75614-87-8, 51-45-6 774
25
Copper Approved Phase 4,Phase 2,Phase 1 15158-11-9, 7440-50-8 27099
26
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 118072-93-8 68740
27
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-24-8 5755
28
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
29
Trastuzumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 180288-69-1 9903
30
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 107868-30-4 60198
31
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
32
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
33
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 120511-73-1 2187
34
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
35 Tegafur Approved Phase 4,Phase 3,Phase 1,Phase 2 17902-23-7
36
Capecitabine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 154361-50-9 60953
37
Sucralfate Approved Phase 4,Phase 3 54182-58-0
38
Amifostine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 20537-88-6 2141
39
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 76-42-6 5284603
40
Hydromorphone Approved, Illicit Phase 4,Phase 3,Phase 1 466-99-9 5284570
41
Sunitinib Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 341031-54-7, 557795-19-4 5329102
42
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 437-38-7 3345
43
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 83-43-2 6741
44
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 1 616-91-1 12035
45
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-63-6 5991
46
Palbociclib Approved Phase 4,Phase 3,Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
47
Fluorouracil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-21-8 3385
48
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
49
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
50
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1 56420-45-2 41867

Interventional clinical trials:

(show top 50) (show all 5000)
id Name Status NCT ID Phase
1 Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography Unknown status NCT00172965 Phase 4
2 rAd-p53 Gene Therapy for Advanced Oral and Maxillofacial Malignant Tumors Unknown status NCT00902083 Phase 4
3 Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate. Unknown status NCT00199277 Phase 4
4 Early Jejunostomy Nutrition Minimizes Time to Chemotherapy Unknown status NCT01766765 Phase 4
5 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4
6 Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia Unknown status NCT02243735 Phase 4
7 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
8 Paracetamol for Cancer Pain Unknown status NCT01313247 Phase 4
9 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4
10 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
11 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4
12 ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial Unknown status NCT02016807 Phase 4
13 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer Unknown status NCT00724581 Phase 4
14 p53 Gene Therapy for Head and Neck Malignant Tumors in Advanced Stage Unknown status NCT00894153 Phase 4
15 THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS Unknown status NCT02241876 Phase 4
16 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4
17 Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery Completed NCT01418118 Phase 4
18 A Study to Evaluate the Efficacy of MuGard for the Amelioration of Oral Mucositis in Head and Neck Cancer Patients Completed NCT01283906 Phase 4
19 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4
20 An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer Completed NCT01006356 Phase 4
21 Absorption of Orally Ingested Phosphate in Refeeding Syndrome Completed NCT02880072 Phase 4
22 An Efficacy and Safety Study of Hydromorphone Oral Osmotic System (OROS) in Korean Participants With Cancer Pain Completed NCT00766831 Phase 4
23 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4
24 Enteral Nutrition Support in Children and Adolescents With Cancer Completed NCT01426750 Phase 4
25 Enteral Nutrition in Cancer Patients Completed NCT01304446 Phase 4
26 Enteral Nutrition in Cancer Patient Completed NCT01302509 Phase 4
27 Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer Completed NCT01989845 Phase 4
28 Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer Completed NCT02074137 Phase 4
29 Mouth Care Regimes During Radiotherapy Completed NCT00138827 Phase 4
30 A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer Completed NCT02581423 Phase 4
31 Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery Completed NCT00571155 Phase 4
32 Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean Patients Completed NCT01621100 Phase 4
33 Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer Completed NCT00082277 Phase 4
34 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4
35 A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer Completed NCT02567331 Phase 4
36 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
37 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4
38 A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Completed NCT02564107 Phase 4
39 Effects of Garlic Supplements on Opioids in Healthy Volunteers Completed NCT00499460 Phase 4
40 Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy Completed NCT00224068 Phase 4
41 RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients Completed NCT01401075 Phase 4
42 VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK Completed NCT01205230 Phase 4
43 Photodynamic Therapy for Oral Leukoplakia and Erythroleukoplakia Completed NCT00155337 Phase 4
44 Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer Completed NCT00375765 Phase 4
45 Tolvaptan in Hyponatremic Cancer Patients Completed NCT01199198 Phase 4
46 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer Completed NCT01296672 Phase 4
47 A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval Completed NCT01328054 Phase 4
48 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations Completed NCT01287754 Phase 4
49 A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression Completed NCT01230710 Phase 4
50 Oral Contraceptive and Cardiovascular Risk in PCOS Completed NCT00593294 Phase 4

Search NIH Clinical Center for Oral Cavity Cancer

Genetic Tests for Oral Cavity Cancer

Genetic tests related to Oral Cavity Cancer:

id Genetic test Affiliating Genes
1 Neoplasm of the Oral Cavity 29

Anatomical Context for Oral Cavity Cancer

MalaCards organs/tissues related to Oral Cavity Cancer:

39
Lymph Node, Neutrophil, Lung, Testes, B Cells, Tongue, Salivary Gland

The Foundational Model of Anatomy Ontology organs/tissues related to Oral Cavity Cancer:

18
The Oral Cavity

Publications for Oral Cavity Cancer

Articles related to Oral Cavity Cancer:

(show top 50) (show all 257)
id Title Authors Year
1
Recent Trends in Oral Cavity Cancer Research Support in the United States. ( 28033064 )
2017
2
Trends in oral cavity cancer incidence, mortality, survival and treatment in the Netherlands. ( 27038013 )
2016
3
Cost-Effectiveness Analysis of Elective Neck Dissection in Patients With Clinically Node-Negative Oral Cavity Cancer. ( 27551113 )
2016
4
Estrogen and Progesterone hormone receptor expression in oral cavity cancer. ( 27475696 )
2016
5
High-Volume Surgeons Deliver Larger Surgical Margins in Oral Cavity Cancer. ( 26896758 )
2016
6
Individualized risk prediction of outcomes for oral cavity cancer patients. ( 27939002 )
2016
7
Decreasing loco-regional recurrence for oral cavity cancer with total Mohs margins technique. ( 27906094 )
2016
8
HPV prevalence and p16INKa overexpression in non smoking non drinking oral cavity cancer patients. ( 26993152 )
2016
9
Impact of postoperative daily image-guided intensity-modulated radiotherapy on overall and local progression-free survival in patients with oral cavity cancer. ( 26906330 )
2016
10
Impact of microsatellite alteration in surgical margins on local recurrence in oral cavity cancer patients. ( 27430224 )
2016
11
CT Accuracy of Extrinsic Tongue Muscle Invasion in Oral Cavity Cancer. ( 28059707 )
2016
12
Increasing use of nonsurgical therapy in advanced-stage oral cavity cancer: A population-based study. ( 27641220 )
2016
13
Neck dissection and stroke in patients with oral cavity cancer: A population-based cohort study. ( 27439202 )
2016
14
Human Papilloma Virus in Oral Cavity Cancer and Relation to Change in Quality of Life Following Treatment-a Pilot Study from Northern India. ( 27872524 )
2016
15
Identification of High-Risk Subgroups of Patients With Oral Cavity Cancer in Need of Postoperative Adjuvant Radiotherapy or Chemo-Radiotherapy. ( 27258508 )
2016
16
Recurrent oral cavity cancer: Patterns of failure after salvage multimodality therapy. ( 28006086 )
2016
17
Validity and reliability of the Korean version of the Speech Handicap Index in patients with oral cavity cancer. ( 26701323 )
2016
18
Submental island flap reconstruction in oral cavity cancer patients with level I lymph node metastasis. ( 27876545 )
2016
19
How does depth of invasion influence the decision to do a neck dissection in clinically N0 oral cavity cancer? ( 26666561 )
2016
20
Electronic Cigarette: Role in the Primary Prevention of Oral Cavity Cancer. ( 27773997 )
2016
21
Outcome of operable oral cavity cancer and impact of maintenance metronomic chemotherapy: A retrospective study from rural India. ( 27275446 )
2016
22
Prognostic value of glucosylceramide synthase and P-glycoprotein expression in oral cavity cancer. ( 27000845 )
2016
23
Beneficial impact of multidisciplinary team management on the survival in different stages of oral cavity cancer patients: results of a nationwide cohort study in Taiwan. ( 25484134 )
2015
24
Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: Systematic review and meta-analysis. ( 26318725 )
2015
25
Leukoplakia, Oral Cavity Cancer Risk, and Cancer Survival in the U.S. Elderly. ( 26159805 )
2015
26
Impact of microvascular free flap reconstruction in oral cavity cancer: our experience in 130 cases. ( 26900243 )
2015
27
Changes and predictors of radiation-induced oral mucositis in patients with oral cavity cancer during active treatment. ( 25586214 )
2015
28
Factors associated with lip and oral cavity cancer. ( 26247186 )
2015
29
Triple-positive pathologic findings in oral cavity cancer are related to a dismal prognosis. ( 26152458 )
2015
30
mTOR and MEK1/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer. ( 26506415 )
2015
31
Complications and mortality following surgery for oral cavity cancer: analysis of 408 cases. ( 26063059 )
2015
32
Dormancy activation mechanism of oral cavity cancer stem cells. ( 25722113 )
2015
33
Time-Dependent Pretreatment with Bevacuzimab Increases Tumor Specific Uptake of Cetuximab in Preclinical Oral Cavity Cancer Studies. ( 25719497 )
2015
34
Oral cavity cancer incidence and mortality in China, 2010. ( 26506867 )
2015
35
Overview of Surgery for Oral Cavity Cancer in Ontario. ( 26040567 )
2015
36
Induction chemotherapy for oral cavity cancer patients: Current status and future perspectives. ( 26522693 )
2015
37
Curcumin-Loaded Chitosan-Coated Nanoparticles as a New Approach for the Local Treatment of Oral Cavity Cancer. ( 26328442 )
2015
38
Human Papillomavirus Infections are Common and Predict Mortality in a Retrospective Cohort Study of Taiwanese Patients With Oral Cavity Cancer. ( 26632712 )
2015
39
Does the use of induction chemotherapy in oral cavity cancer compromise subsequent loco-regional treatment delivery: Results from a matched pair analysis. ( 26960501 )
2015
40
Recurrence and cancer-specific survival according to the expression of IL-4RI+ and IL-13RI+1 in patients with oral cavity cancer. ( 25483786 )
2015
41
Designing and Dosimetry of a Shield for Photon Fields of Radiation Therapy in Oral Cavity Cancer. ( 26120570 )
2015
42
Individualized Risk Estimation for Postoperative Complications After Surgery for Oral Cavity Cancer. ( 26469394 )
2015
43
Staging of early lymph node metastases with the sentinel lymph node technique and predictive factors in T1/T2 oral cavity cancer: A retrospective single-center study. ( 26040238 )
2015
44
Use of customized intraoral mold high-dose-rate brachytherapy in the treatment of oral cavity cancer in an elderly patient. ( 25413412 )
2015
45
Oral cavity cancer trends over the past 25 years in Hong Kong: a multidirectional statistical analysis. ( 26205649 )
2015
46
Oral Cavity Cancer: Risk Factors, Pathology, and Management. ( 26088938 )
2015
47
Validation of methylation markers for diagnosis of oral cavity cancer. ( 25686481 )
2015
48
Bringing Light to Dental Trauma and Oral Cavity Cancer-Reply. ( 26583510 )
2015
49
Feasibility of Real-Time Near-Infrared Fluorescence Tracer Imaging in Sentinel Node Biopsy for Oral Cavity Cancer Patients. ( 26467454 )
2015
50
Bringing Light to Dental Trauma and Oral Cavity Cancer. ( 26583509 )
2015

Variations for Oral Cavity Cancer

ClinVar genetic disease variations for Oral Cavity Cancer:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
2 PTEN NM_000314.6(PTEN): c.388C> G (p.Arg130Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121909224 GRCh37 Chromosome 10, 89692904: 89692904

Expression for Oral Cavity Cancer

Search GEO for disease gene expression data for Oral Cavity Cancer.

Pathways for Oral Cavity Cancer

Pathways related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 25)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.27 EGFR ERBB2 HSP90B1 IL18 MCL1 SOX2
2
Show member pathways
12.62 CASP8 EGFR FADD HSP90B1 TNFRSF10B VEGFA
3
Show member pathways
12.56 ALDH2 CYP1A1 CYP2E1 GSTM1 GSTT1
4
Show member pathways
12.51 CASP8 FADD TLR6 TNFRSF10B VEGFA
5 12.3 CASP8 EDNRB EGFR ERBB2 FADD HSP90B1
6 12.12 CASP8 FADD IL18 TLR6
7
Show member pathways
12.1 ALDH2 CAT CYP1A1 CYP2E1
8 12.06 CASP8 FADD GDF15 MCL1 TNFRSF10B
9 12.01 CASP8 EGFR FADD VEGFA
10 11.94 GSTM1 GSTT1 HSP90B1 VEGFA
11 11.9 EGFR GDF15 MCL1 TNFRSF10B
12
Show member pathways
11.81 CASP8 EGFR ERBB2 HSP90B1 TLR6
13 11.79 EGFR ERBB2 VEGFA
14
Show member pathways
11.76 EGFR ERBB2 VEGFA
15
Show member pathways
11.71 CASP8 FADD MCL1
16 11.71 HSP90B1 IL18 MCL1 SOX2 VEGFA
17 11.63 EGFR ERBB2 VEGFA
18
Show member pathways
11.63 CYP1A1 CYP2E1 GSTM1 GSTT1
19 11.39 CYP1A1 EGFR VEGFA
20 11.31 CASP8 FADD TNFRSF10B
21 10.88 CASP8 ERBB2 FADD GSTM1 GSTT1
22
Show member pathways
10.72 ALDH2 CAT CYP2E1
23 10.64 CASP8 FADD
24 10.64 CYP1A1 CYP2E1 GSTM1 GSTT1
25 10.33 CYP2E1 GSTM1

GO Terms for Oral Cavity Cancer

Cellular components related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 death-inducing signaling complex GO:0031264 9.26 CASP8 FADD
2 ripoptosome GO:0097342 9.16 CASP8 FADD
3 membrane raft GO:0045121 9.02 CASP8 EDNRB EGFR FADD TLR6
4 CD95 death-inducing signaling complex GO:0031265 8.96 CASP8 FADD

Biological processes related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 25)
id Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.88 CAT EDNRB EGFR HSP90B1 MCL1 VEGFA
2 response to lipopolysaccharide GO:0032496 9.85 CASP8 CYP1A1 EDNRB TNFRSF10B
3 response to hypoxia GO:0001666 9.81 CAT CYP1A1 HSP90B1 VEGFA
4 response to estradiol GO:0032355 9.8 CASP8 CAT EGFR
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.8 CASP8 FADD TLR6 TNFRSF10B
6 positive regulation of protein phosphorylation GO:0001934 9.78 EDNRB EGFR ERBB2 VEGFA
7 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.77 CASP8 FADD TNFRSF10B
8 cellular response to organic cyclic compound GO:0071407 9.76 CASP8 CYP1A1 IL18
9 positive regulation of epithelial cell proliferation GO:0050679 9.74 EGFR ERBB2 VEGFA
10 regulation of apoptotic process GO:0042981 9.72 CASP8 FADD GDF15 MCL1 TNFRSF10B
11 positive regulation of MAP kinase activity GO:0043406 9.71 EGFR ERBB2 VEGFA
12 cellular response to growth factor stimulus GO:0071363 9.7 CAT EGFR ERBB2
13 negative regulation of ERBB signaling pathway GO:1901185 9.62 EGFR ERBB2
14 positive regulation of macrophage differentiation GO:0045651 9.61 CASP8 FADD
15 regulation of necroptotic process GO:0060544 9.61 CASP8 FADD
16 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.61 CASP8 FADD TNFRSF10B
17 T-helper 1 type immune response GO:0042088 9.59 IL18 TLR6
18 activation of cysteine-type endopeptidase activity GO:0097202 9.58 CASP8 FADD
19 death-inducing signaling complex assembly GO:0071550 9.56 CASP8 FADD
20 cellular response to mechanical stimulus GO:0071260 9.56 CASP8 EGFR FADD TNFRSF10B
21 response to ozone GO:0010193 9.46 CAT CYP2E1
22 TRAIL-activated apoptotic signaling pathway GO:0036462 9.37 CASP8 FADD
23 regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902041 9.33 CASP8 FADD TNFRSF10B
24 activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway GO:0097296 9.13 CASP8 FADD TNFRSF10B
25 cell surface receptor signaling pathway GO:0007166 9.1 CASP8 EDNRB EGFR ERBB2 FADD TNFRSF10B

Molecular functions related to Oral Cavity Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.43 EGFR ERBB2 HSP90B1
2 enzyme binding GO:0019899 9.35 CAT CYP1A1 CYP2E1 EGFR GSTM1
3 death receptor binding GO:0005123 9.32 CASP8 FADD
4 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.16 EGFR ERBB2
5 death effector domain binding GO:0035877 8.62 CASP8 FADD

Sources for Oral Cavity Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....